Table 1 (abstract P147). Comparison of medication possession ratio (MPR) of colchicine between FMF patients treated with IL-1 inhibitors Versus patients without IL-1 inhibitors treatment
From: Proceedings of the 28th European Paediatric Rheumatology Congress (PReS 2022)
Parameter | With IL-1 inhibitors – “study group” (n=108) | Without IL-1 inhibitors – “matched group” (N=432) | P-value |
|---|---|---|---|
Age category, years | |||
≤6 | 74.9±24.9 (N=32) | 75.8±33.7 (N=23) | 0.9 |
7-14 | 90.2±53.6 (N=24) | 75.6±70.3 (N=93) | 0.09 |
15-29 | 76.5±47.9 (N=29) | 91.1±123.3 (N=101) | 0.3 |
≥30 | 75.8±33.7 (N=23) | 77±49.9 (N=112) | 0.6 |
Sex | |||
Male | 75.7±49.9 (N=48) | 79.2± 65.5 (N=192) | 0.9 |
Female | 81.4±33.2 (N=60) | 85.1±91.0 (N=240) | 0.03 |
Time of colchicine use | |||
< 8 years | 102.8±46.2 (N=42) | 100.9±99.5 (N=245) | 0.2 |
8-15 years | 66.6±35.8 (N=26) | 56.7±36.5 (N=103) | 0.2 |
> 15 years | 61.9±24.8 (N=40) | 60.4±25.8 (N=84) | 0.7 |